DiagnoCure joins the OTCQX Marketplace and S&P Corporation Records Listing
02 Aprile 2013 - 1:00PM
OTC Markets
DiagnoCure joins the OTCQX Marketplace and S&P Corporation
Records Listing
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
DiagnoCure joins the OTCQX Marketplace and S&P Corporation
Records Listing
PR Newswire
QUEBEC CITY, April 2, 2013
QUEBEC CITY, April 2, 2013 /PRNewswire/ - DiagnoCure, Inc.
(TSX: CUR)
(OTCQX: DGCRF), today announced that the Company's stock is now
trading
on OTCQX International under the symbol "DGCRF". OTCQX is the best
U.S. OTC
marketplace, providing an opportunity to significantly broaden
and
enhance DiagnoCure's access and exposure within the U.S. market.
The
OTCQX marketplace has earned an exemplary reputation for providing
U.S.
investors with improved liquidity, transparency, superior
information,
and easy access through their U.S. regulated broker dealers. It is
also
recognized within the industry for maintaining rigid quotation
standards for companies that trade there. Investors can find
current
financial disclosures and Real-Time Level 2 quotes for DiagnoCure
on www.otcmarkets.com.
In addition, DiagnoCure announced today that its company
information
would be made available via Standard & Poor's Corporation
Records
Listing Program. As part of the program, a full description of
DiagnoCure will be published in the Daily News Section of Standard
&
Poors' Corporation Records, a recognized securities manual for
secondary trading in up to 38 states under the Blue Sky Laws.
Standard
& Poor's Corporation Records is available in print, CD-ROM, and
via the
web at www.netadvantage.standardandpoors.com as well as through
numerous electronic vendors. The company information
about DiagnoCure to be made available through this program includes
an
in-depth description of the DiagnoCure's business operations,
share
price, dividend history, shares outstanding, company financial
position, earnings, and full income statement and balance
sheet.
Canaccord Genuity will be the market maker of DiagnoCure's
stock.
Canaccord Genuity is a global, full-service investment bank focused
on
growth companies and is one of the largest market maker in
the United
States.
Dorsey & Whitney LLP will serve as DiagnoCure's Principal
American
Liaison ("PAL") on OTCQX, responsible for providing guidance on
OTCQX
requirements and U.S. securities laws.
"Trading on OTCQX International will provide enhanced access to
U.S.
investors and the ability for DiagnoCure to diversify its
shareholder
base," said Chantal Miklosi, Chief
Financial Officer of DiagnoCure. "We
believe that trading on the OTCQX marketplace is in the best
interest
of shareholders and will enable the Company to enhance the
market
liquidity of DiagnoCure shares."
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high-value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory.
PrevistageTM GCC is currently available for
licensing. The Corporation has granted a
worldwide exclusive license to Gen-Probe, now a wholly-owned
subsidiary
of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for
the
development and commercialization of a prostate cancer test using
PCA3,
DiagnoCure's proprietary molecular biomarker. Hologic
Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the
United States. For
more information, visit www.diagnocure.com.
Forward?looking statements
This release contains "forward?looking statements," within the
meaning
of applicable United States and
Canadian securities laws, that involve
known and unknown risks, uncertainties and assumptions that may
cause
actual results to differ materially from those expected. By their
very
nature, forward?looking statements are based on expectations
and
hypotheses and also involve risks and uncertainties, known and
unknown,
many of which are beyond DiagnoCure's control. As a result,
investors
are cautioned not to place undue reliance on these
forward?looking
statements. Such forward-looking statements include the outcome
of
research and development projects, clinical studies, future
revenues,
the benefits of being quoted on the OTCQX and the improved
liquidity of
the Company's shares when traded on the OTCQX and are based on
management expectations. In addition, the reader is referred to
the
applicable general risks and uncertainties described in
DiagnoCure's
most recent Annual Information Form under the heading "Risk
Factors".
DiagnoCure undertakes no obligation to publicly update or revise
any
forward?looking statements contained herein unless required by
the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.
Grafico Azioni Diagnocure (CE) (USOTC:DGCRF)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Diagnocure (CE) (USOTC:DGCRF)
Storico
Da Lug 2023 a Lug 2024